Evolent Health, Inc (NYSE:EVH) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a research report on Thursday. Cowen and Company reissued an “outperform” rating and set a $33.00 price objective (down from $35.00) on shares of Evolent Health in a research report on Wednesday. Robert W. Baird set a $35.00 price objective on shares of Evolent Health and gave the company a “buy” rating in a research report on Tuesday. ValuEngine downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Leerink Swann reissued an “outperform” rating and set a $32.00 price objective (up from $30.00) on shares of Evolent Health in a research report on Monday, June 19th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $29.90.

Evolent Health (NYSE EVH) opened at 18.40 on Friday. Evolent Health has a 52 week low of $14.50 and a 52 week high of $27.50. The company’s market capitalization is $1.21 billion. The company’s 50-day moving average is $24.73 and its 200 day moving average is $22.68.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Monday, August 7th. The technology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The business had revenue of $107.30 million for the quarter, compared to the consensus estimate of $104.45 million. Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The company’s quarterly revenue was up 89.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.20) EPS. On average, analysts forecast that Evolent Health will post ($0.41) EPS for the current fiscal year.

WARNING: “BidaskClub Lowers Evolent Health, Inc (NYSE:EVH) to Sell” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/12/bidaskclub-lowers-evolent-health-inc-nyseevh-to-sell.html.

In other news, President Seth Blackley sold 15,000 shares of the business’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $25.00, for a total transaction of $375,000.00. Following the sale, the president now owns 760,944 shares in the company, valued at approximately $19,023,600. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Frank J. Williams sold 16,300 shares of the business’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $23.73, for a total transaction of $386,799.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,153,967 shares of company stock worth $253,648,377. Company insiders own 8.79% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the company. State Street Corp boosted its position in shares of Evolent Health by 5.2% in the fourth quarter. State Street Corp now owns 250,000 shares of the technology company’s stock worth $3,699,000 after buying an additional 12,339 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Evolent Health by 134.7% in the fourth quarter. AQR Capital Management LLC now owns 25,657 shares of the technology company’s stock worth $380,000 after buying an additional 14,723 shares during the last quarter. Teachers Advisors LLC boosted its position in shares of Evolent Health by 5.1% in the fourth quarter. Teachers Advisors LLC now owns 25,119 shares of the technology company’s stock worth $372,000 after buying an additional 1,211 shares during the last quarter. Macquarie Group Ltd. boosted its position in shares of Evolent Health by 18.6% in the fourth quarter. Macquarie Group Ltd. now owns 113,011 shares of the technology company’s stock worth $1,673,000 after buying an additional 17,718 shares during the last quarter. Finally, Bank of Montreal Can boosted its position in shares of Evolent Health by 4,249.7% in the first quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock worth $138,000 after buying an additional 6,077 shares during the last quarter. Institutional investors own 73.16% of the company’s stock.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.